NZ593225A - Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis - Google Patents
Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosisInfo
- Publication number
- NZ593225A NZ593225A NZ593225A NZ59322507A NZ593225A NZ 593225 A NZ593225 A NZ 593225A NZ 593225 A NZ593225 A NZ 593225A NZ 59322507 A NZ59322507 A NZ 59322507A NZ 593225 A NZ593225 A NZ 593225A
- Authority
- NZ
- New Zealand
- Prior art keywords
- colorectal cancer
- cmyc
- gene expression
- human subject
- clinical outcome
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title abstract 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 title abstract 4
- 230000014509 gene expression Effects 0.000 title abstract 4
- 101100239628 Danio rerio myca gene Proteins 0.000 title abstract 3
- 238000004393 prognosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002596 correlated effect Effects 0.000 abstract 1
- 238000002271 resection Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75839206P | 2006-01-11 | 2006-01-11 | |
| US80027706P | 2006-05-12 | 2006-05-12 | |
| US81007706P | 2006-05-31 | 2006-05-31 | |
| NZ569788A NZ569788A (en) | 2006-01-11 | 2007-01-11 | RNA transcript of BGN as a gene expression markers for colorectal cancer prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ593225A true NZ593225A (en) | 2012-10-26 |
Family
ID=38257063
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ593226A NZ593226A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (efnb2) for colorectal cancer prognosis |
| NZ593227A NZ593227A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (MYBL2) for colorectal cancer prognosis |
| NZ569788A NZ569788A (en) | 2006-01-11 | 2007-01-11 | RNA transcript of BGN as a gene expression markers for colorectal cancer prognosis |
| NZ593229A NZ593229A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (gadd45b) for colorectal cancer prognosis |
| NZ593224A NZ593224A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (fap) for colorectal cancer prognosis |
| NZ593225A NZ593225A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis |
| NZ593228A NZ593228A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (inhba) for colorectal cancer prognosis |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ593226A NZ593226A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (efnb2) for colorectal cancer prognosis |
| NZ593227A NZ593227A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (MYBL2) for colorectal cancer prognosis |
| NZ569788A NZ569788A (en) | 2006-01-11 | 2007-01-11 | RNA transcript of BGN as a gene expression markers for colorectal cancer prognosis |
| NZ593229A NZ593229A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (gadd45b) for colorectal cancer prognosis |
| NZ593224A NZ593224A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (fap) for colorectal cancer prognosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ593228A NZ593228A (en) | 2006-01-11 | 2007-01-11 | Gene expression markers (inhba) for colorectal cancer prognosis |
Country Status (14)
| Country | Link |
|---|---|
| US (10) | US7695913B2 (enExample) |
| EP (9) | EP2412824B1 (enExample) |
| JP (7) | JP5297202B2 (enExample) |
| KR (1) | KR20090003178A (enExample) |
| AU (1) | AU2007204826B2 (enExample) |
| BR (1) | BRPI0706511A2 (enExample) |
| CA (1) | CA2636984A1 (enExample) |
| DK (1) | DK1974058T3 (enExample) |
| ES (1) | ES2491222T3 (enExample) |
| IL (1) | IL192794A (enExample) |
| MX (1) | MX2008008973A (enExample) |
| NO (1) | NO20083461L (enExample) |
| NZ (7) | NZ593226A (enExample) |
| WO (1) | WO2007082099A2 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2506066A1 (en) | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
| EP2947160B1 (en) | 2004-04-09 | 2017-07-12 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| NZ593226A (en) * | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (efnb2) for colorectal cancer prognosis |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| CN103424541B (zh) | 2006-05-18 | 2018-01-30 | 分子压型学会股份有限公司 | 确定针对病状的个性化医疗介入的系统和方法 |
| US20080234946A1 (en) * | 2007-03-22 | 2008-09-25 | University Of South Florida | Predictive radiosensitivity network model |
| US20090076734A1 (en) | 2007-03-22 | 2009-03-19 | Torres-Roca Javier F | Gene Signature for the Prediction of Radiation Therapy Response |
| EP3851856A3 (en) | 2007-03-27 | 2021-11-03 | Immunovia AB | Method, array and use thereof |
| US20090123920A1 (en) * | 2007-11-08 | 2009-05-14 | Maher Albitar | Jak2 mutations |
| ES2332167B1 (es) | 2007-12-04 | 2010-10-25 | Universidad Autonoma De Madrid | Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal. |
| WO2009123634A1 (en) * | 2008-04-02 | 2009-10-08 | Regents Of The University Of California | Systems and methods for predicting response of biological samples |
| US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| NZ589143A (en) | 2008-05-14 | 2012-02-24 | Genomic Health Inc | Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels |
| US20100029748A1 (en) * | 2008-08-04 | 2010-02-04 | Sloan-Kettering Institute For Cancer Research | Metastasis Promoting Genes and Proteins |
| WO2012006632A2 (en) | 2010-07-09 | 2012-01-12 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| US10359425B2 (en) * | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| US20100221752A2 (en) * | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
| US20110257034A1 (en) * | 2008-10-10 | 2011-10-20 | Cornell University | Methods for identifying genes which predict disease outcome for patients with colon cancer |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| US8765383B2 (en) * | 2009-04-07 | 2014-07-01 | Genomic Health, Inc. | Methods of predicting cancer risk using gene expression in premalignant tissue |
| NZ596054A (en) * | 2009-05-01 | 2013-07-26 | Genomic Health Inc | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
| TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| US20120053253A1 (en) | 2010-07-07 | 2012-03-01 | Myriad Genetics, Incorporated | Gene signatures for cancer prognosis |
| EP3147373B1 (en) | 2010-07-27 | 2019-05-15 | Genomic Health, Inc. | Method for using gene expression to determine prognosis of prostate cancer |
| SG187045A1 (en) | 2010-08-13 | 2013-02-28 | Somalogic Inc | Pancreatic cancer biomarkers and uses thereof |
| US9605319B2 (en) | 2010-08-30 | 2017-03-28 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| MY166040A (en) | 2010-09-15 | 2018-05-21 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| SG192108A1 (en) * | 2011-01-25 | 2013-08-30 | Almac Diagnostics Ltd | Colon cancer gene expression signatures and methods of use |
| US10308980B2 (en) | 2011-11-04 | 2019-06-04 | Oslo Universitetssykehus Hf | Methods and biomarkers for analysis of colorectal cancer |
| CA2857073A1 (en) | 2011-11-28 | 2013-06-06 | Institucio Catalana De Recerca I Estudis Avancats | Methods and kits for the prognosis of colorectal cancer |
| EP2794924B1 (en) | 2011-12-22 | 2019-02-06 | Baylor Research Institute | Identification of mirna signatures in human colorectal cancer |
| AU2013208757A1 (en) * | 2012-01-09 | 2014-07-24 | Oslo Universitetssykehus Hf | Methods and biomarkers for analysis of colorectal cancer |
| EP3179393B1 (en) | 2012-01-31 | 2020-07-08 | Genomic Health, Inc. | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| WO2013150167A2 (es) | 2012-04-03 | 2013-10-10 | Servicio Andaluz De Salud | Modelo de expresión de microarn como indicador de supervivencia en pacientes de cancer colorrectal metastásico |
| US20160222457A1 (en) * | 2012-11-14 | 2016-08-04 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying malignant skin lesions |
| WO2014078700A1 (en) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| ES2475366B1 (es) * | 2012-12-10 | 2015-05-05 | Fundación Imdea Alimentación | Métodos y kits para el pronóstico del cáncer colorrectal |
| JP2016513462A (ja) | 2013-03-14 | 2016-05-16 | アボツト・モレキユラー・インコーポレイテツド | 細胞作製物及び細胞支持体、及びテラノーシスにおけるその使用 |
| AR096507A1 (es) * | 2013-05-30 | 2016-01-13 | Fundació Institució Catalana De Recerca I Estudis Avançats | Métodos y kits para el pronóstico del cáncer colorrectal |
| US10185809B1 (en) * | 2013-10-15 | 2019-01-22 | Iqvia Inc. | Patient projection methodology |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| AU2015237229A1 (en) * | 2014-03-28 | 2016-11-10 | Applied Proteomics, Inc. | Protein biomarker profiles for detecting colorectal tumors |
| EP3143160B1 (en) | 2014-05-13 | 2019-11-06 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| WO2016025717A1 (en) | 2014-08-14 | 2016-02-18 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| CA2965408C (en) | 2014-10-24 | 2023-10-24 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities |
| BR112017007965A8 (pt) | 2014-10-24 | 2022-11-08 | Koninklijke Philips Nv | Método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit |
| CA2965217A1 (en) | 2014-10-24 | 2016-04-28 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities |
| WO2016084130A1 (ja) | 2014-11-25 | 2016-06-02 | 三菱電機株式会社 | 空圧式アクチュエータ |
| US20180148789A1 (en) * | 2014-12-01 | 2018-05-31 | University Of Southern California | Methods for treating and assessing tumor invasion and metastasis |
| EP3073268A1 (en) * | 2015-03-27 | 2016-09-28 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Biomarker panel for diagnosing cancer |
| US10435755B2 (en) | 2015-03-27 | 2019-10-08 | Exact Sciences Development Company, Llc | Detecting esophageal disorders |
| EP3281016A1 (en) | 2015-04-10 | 2018-02-14 | Applied Proteomics Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
| CN108271422A (zh) * | 2015-06-25 | 2018-07-10 | 株式会社国际电气通信基础技术研究所 | 基于器官间串扰系统的预测装置及预测程序 |
| WO2017029215A1 (en) | 2015-08-14 | 2017-02-23 | Koninklijke Philips N.V. | Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression |
| CN114778845A (zh) | 2016-03-29 | 2022-07-22 | 无限生物制药公司 | 药物组合物或食品组合物及评价活性成分体内效果的方法 |
| EP3438282A4 (en) | 2016-03-29 | 2020-05-06 | Advanced Telecommunications Research Institute International | METHOD FOR SCREENING CANDIDATE SUBSTANCES FOR AN ACTIVE COMPONENT TO PREVENT OR TREAT AT LEAST ONE SELECTED DISEASE IN THE KIDNEY HYPOFUNCTION GROUP, CHRONIC KIDNEY DISEASE AND KIDNEY DEFICIENCY |
| AU2017261688B2 (en) | 2016-05-10 | 2022-09-29 | Mayo Foundation For Medical Education And Research | Methods and materials for staging and treating skin cancer |
| WO2018165532A1 (en) | 2017-03-10 | 2018-09-13 | Baylor Research Institute | Methods for diagnosing and treating gastric cancer using mirna expression |
| WO2018224731A1 (en) * | 2017-06-05 | 2018-12-13 | Ls Cancerdiag Oy | A method for determining whether a subject is at risk to develop cancer and tools related thereto |
| EP3461915A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3461916A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
| JP7027179B2 (ja) * | 2018-01-24 | 2022-03-01 | キヤノン株式会社 | 給送回転体、シート給送装置及び画像形成装置 |
| EP3762493A4 (en) | 2018-03-08 | 2021-11-24 | University of Notre Dame du Lac | SYSTEMS AND METHODS FOR EVALUATING A MOLECULAR SUB-TYPE OF COLORECTAL CANCER AND RISK OF RECURRENCE AND DETERMINATION AND ADMINISTRATION OF TREATMENT PROTOCOLS BASED ON THESE LATEST |
| KR102007450B1 (ko) * | 2018-05-31 | 2019-08-05 | 한국과학기술연구원 | 대장암 치료제 발굴을 위한 신규 표적 치료 작용점의 스크리닝 방법 및 이를 이용하여 선별한 대장암 치료 예후 바이오마커 |
| US12473599B2 (en) | 2018-07-25 | 2025-11-18 | Skylinedx B.V. | Gene signatures for predicting metastasis of melanoma and patient prognosis |
| WO2020112853A1 (en) | 2018-11-28 | 2020-06-04 | Genascence Corporation | Methods and compositions for treating osteoarthritis |
| WO2020123699A1 (en) * | 2018-12-11 | 2020-06-18 | The Trustees Of Columbia University In The City Of New York | Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof |
| CN110257518B (zh) * | 2019-07-01 | 2022-08-02 | 复旦大学附属中山医院 | 一种用于预测转移性结直肠癌转化治疗疗效的基因集 |
| US12057959B2 (en) * | 2019-12-31 | 2024-08-06 | Mcafee, Llc | Device identification |
| KR102263984B1 (ko) * | 2020-02-21 | 2021-06-11 | 재단법인 아산사회복지재단 | 직장암 환자에서 수술-전 화학방사선치료의 반응을 예측하기 위한 분석방법 |
| KR102535150B1 (ko) * | 2020-04-14 | 2023-05-23 | 주식회사 베르티스 | 암의 예후 예측용 조성물 |
| EP4143309A4 (en) * | 2020-04-29 | 2025-01-01 | Freenome Holdings, Inc. | Rna markers and methods for identifying colon cell proliferative disorders |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| CN112322730B (zh) * | 2020-10-16 | 2023-04-18 | 上海市第一人民医院 | 预测肿瘤耐药、复发的标志物kifc1及其抑制剂和应用 |
| EP4026918A1 (en) | 2021-01-12 | 2022-07-13 | Koninklijke Philips N.V. | Prediction of an outcome of a colorectal cancer subject |
| CN113667673B (zh) * | 2021-07-15 | 2024-02-06 | 武汉血液中心 | 一种类孟买血型FUT1 236delG等位基因及其检测方法和应用 |
| KR20230059642A (ko) * | 2021-10-26 | 2023-05-03 | 사회복지법인 삼성생명공익재단 | miRNA를 포함하는 대장암의 치료 및 전이 억제용 조성물 및 이의 용도 |
| CN116735874B (zh) * | 2022-03-11 | 2025-09-23 | 上海市免疫学研究所 | 结直肠癌肿瘤边界细胞亚群标志物组合及其应用 |
| WO2024035653A1 (en) * | 2022-08-06 | 2024-02-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Predictive biomarker in avastin in colon cancer |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020172987A1 (en) | 1998-02-12 | 2002-11-21 | Terstappen Leon W.M.M. | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
| AU4158799A (en) | 1998-06-06 | 1999-12-30 | Genostic Pharma Limited | Probes used for genetic filing |
| JP2003528564A (ja) | 1998-06-06 | 2003-09-30 | ジェノスティック ファーマ リミテッド | 遺伝的プロファイリングに使用するプローブ |
| WO2000024940A1 (en) | 1998-10-28 | 2000-05-04 | Vysis, Inc. | Cellular arrays and methods of detecting and using genetic disorder markers |
| EP0999016B1 (en) * | 1998-11-06 | 2001-07-11 | Temco S. R. L. | Cutter for cross cutting of webs |
| US6960439B2 (en) | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US6692916B2 (en) | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
| CA2384713A1 (en) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| WO2001041815A2 (en) | 1999-12-10 | 2001-06-14 | Whitehead Institute For Biomedical Research | Metastasis genes and uses thereof |
| US7029677B2 (en) * | 2000-01-25 | 2006-04-18 | Nuvelo, Inc. | Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells |
| US20030148327A1 (en) | 2000-04-06 | 2003-08-07 | Alexander Olek | Diagnosis of diseases associated with metastasis |
| WO2005000087A2 (en) | 2003-06-03 | 2005-01-06 | Chiron Corporation | Gene products differentially expressed in cancerous colon cells and their methods of use ii |
| US20030166064A1 (en) | 2000-08-03 | 2003-09-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| US20020110832A1 (en) | 2000-08-03 | 2002-08-15 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| US20020136728A1 (en) | 2000-08-03 | 2002-09-26 | King Gordon E | Compositions and methods for the therapy and diagnosis of colon cancer |
| US20030077568A1 (en) | 2000-09-15 | 2003-04-24 | Gish Kurt C. | Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| US7105293B2 (en) | 2000-09-19 | 2006-09-12 | Whitehead Institute For Biomedical Research | Genetic markers for tumors |
| US20020150922A1 (en) | 2000-11-20 | 2002-10-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| AU2002251844A1 (en) * | 2001-02-02 | 2002-10-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| EP1402068A4 (en) * | 2001-05-09 | 2006-07-12 | Univ Cleveland Hospitals | EVALUATION OF SKIN DAMAGE CAUSED BY ULTRAVIOLET RAYS USING NEW GENE MARKERS, METHODS AND COMPOSITIONS THEREOF |
| US20030148314A1 (en) * | 2001-08-01 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer |
| US7622260B2 (en) | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
| KR20040064275A (ko) | 2001-11-09 | 2004-07-16 | 소스 프리시전 메디슨, 인코포레이티드 | 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인 |
| US20030225526A1 (en) | 2001-11-14 | 2003-12-04 | Golub Todd R. | Molecular cancer diagnosis using tumor gene expression signature |
| US20030148410A1 (en) * | 2001-12-10 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer |
| US20070166704A1 (en) | 2002-01-18 | 2007-07-19 | Fei Huang | Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways |
| US7955800B2 (en) | 2002-06-25 | 2011-06-07 | Advpharma Inc. | Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients |
| WO2004025258A2 (en) | 2002-09-10 | 2004-03-25 | Sydney Kimmel Cancer Center | Gene segregation and biological sample classification methods |
| AU2003304203A1 (en) | 2002-10-29 | 2005-01-04 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
| US7767391B2 (en) | 2003-02-20 | 2010-08-03 | Genomic Health, Inc. | Use of intronic RNA to measure gene expression |
| WO2005008213A2 (en) | 2003-07-10 | 2005-01-27 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| WO2005015236A2 (en) | 2003-07-18 | 2005-02-17 | Roche Diagnostics Gmbh | A method for predicting the progression of adenocarcinoma |
| US20050014165A1 (en) | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
| AU2004262369A1 (en) * | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| EP1892306A3 (en) | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| WO2005076005A2 (en) | 2004-01-30 | 2005-08-18 | Medizinische Universität Wien | A method for classifying a tumor cell sample based upon differential expression of at least two genes |
| US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
| JP2007532889A (ja) | 2004-04-16 | 2007-11-15 | モナシュ ユニバーシティー | 癌の進行度をモニタリングする方法 |
| WO2006010150A2 (en) | 2004-07-15 | 2006-01-26 | University Of Utah Research Foundation | Housekeeping genes and methods for identifying the same |
| US20060183893A1 (en) | 2005-01-25 | 2006-08-17 | North Don A | Nucleic acids for apoptosis of cancer cells |
| EP2083088A3 (en) | 2005-04-07 | 2009-10-14 | Novartis Vaccines and Diagnostics, Inc. | Cancer-related genes |
| EP1907858A4 (en) | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| WO2007061876A2 (en) | 2005-11-23 | 2007-05-31 | University Of Utah Research Foundation | Methods and compositions involving intrinsic genes |
| WO2007070621A2 (en) | 2005-12-13 | 2007-06-21 | Children's Medical Center Corporation | Prognosis indicators for solid human tumors |
| NZ544432A (en) | 2005-12-23 | 2009-07-31 | Pacific Edge Biotechnology Ltd | Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS |
| NZ593226A (en) | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (efnb2) for colorectal cancer prognosis |
| US20100009905A1 (en) | 2006-03-24 | 2010-01-14 | Macina Roberto A | Compositions and Methods for Detection, Prognosis and Treatment of Colon Cancer |
| EP2140020A2 (en) | 2007-03-15 | 2010-01-06 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| US8765383B2 (en) | 2009-04-07 | 2014-07-01 | Genomic Health, Inc. | Methods of predicting cancer risk using gene expression in premalignant tissue |
| NZ596054A (en) | 2009-05-01 | 2013-07-26 | Genomic Health Inc | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
-
2007
- 2007-01-11 NZ NZ593226A patent/NZ593226A/xx unknown
- 2007-01-11 EP EP10194720.8A patent/EP2412824B1/en not_active Not-in-force
- 2007-01-11 NZ NZ593227A patent/NZ593227A/xx unknown
- 2007-01-11 EP EP10177406.5A patent/EP2377950B1/en not_active Not-in-force
- 2007-01-11 NZ NZ569788A patent/NZ569788A/en unknown
- 2007-01-11 EP EP07717900.0A patent/EP1974058B1/en active Active
- 2007-01-11 NZ NZ593229A patent/NZ593229A/xx unknown
- 2007-01-11 NZ NZ593224A patent/NZ593224A/xx unknown
- 2007-01-11 ES ES07717900.0T patent/ES2491222T3/es active Active
- 2007-01-11 CA CA002636984A patent/CA2636984A1/en not_active Abandoned
- 2007-01-11 NZ NZ593225A patent/NZ593225A/xx unknown
- 2007-01-11 DK DK07717900.0T patent/DK1974058T3/da active
- 2007-01-11 MX MX2008008973A patent/MX2008008973A/es active IP Right Grant
- 2007-01-11 EP EP10194717A patent/EP2412822A1/en not_active Withdrawn
- 2007-01-11 NZ NZ593228A patent/NZ593228A/xx unknown
- 2007-01-11 EP EP10194715A patent/EP2407553A1/en not_active Withdrawn
- 2007-01-11 EP EP10194719.0A patent/EP2412823B1/en not_active Not-in-force
- 2007-01-11 EP EP10194714.1A patent/EP2412821B1/en not_active Not-in-force
- 2007-01-11 US US11/653,102 patent/US7695913B2/en active Active
- 2007-01-11 BR BRPI0706511-6A patent/BRPI0706511A2/pt not_active IP Right Cessation
- 2007-01-11 KR KR1020087019544A patent/KR20090003178A/ko not_active Withdrawn
- 2007-01-11 EP EP10194713A patent/EP2412820A1/en not_active Withdrawn
- 2007-01-11 AU AU2007204826A patent/AU2007204826B2/en active Active
- 2007-01-11 WO PCT/US2007/000995 patent/WO2007082099A2/en not_active Ceased
- 2007-01-11 JP JP2008550454A patent/JP5297202B2/ja active Active
- 2007-01-11 EP EP10194722A patent/EP2400036A1/en not_active Withdrawn
-
2008
- 2008-07-13 IL IL192794A patent/IL192794A/en active IP Right Grant
- 2008-08-08 NO NO20083461A patent/NO20083461L/no not_active Application Discontinuation
-
2010
- 2010-01-29 US US12/696,934 patent/US8153378B2/en active Active
- 2010-10-25 US US12/911,544 patent/US8153380B2/en active Active
- 2010-10-25 US US12/911,551 patent/US8026060B2/en active Active
- 2010-10-25 US US12/911,532 patent/US8029995B2/en active Active
- 2010-10-25 US US12/911,526 patent/US8153379B2/en active Active
- 2010-10-25 US US12/911,519 patent/US8273537B2/en active Active
-
2011
- 2011-01-19 US US13/009,733 patent/US8198024B2/en active Active
-
2012
- 2012-03-06 US US13/413,338 patent/US8367345B2/en active Active
- 2012-12-13 JP JP2012272400A patent/JP5486664B2/ja active Active
- 2012-12-28 US US13/729,462 patent/US20130102492A1/en not_active Abandoned
-
2013
- 2013-06-13 JP JP2013124952A patent/JP2013215201A/ja active Pending
- 2013-06-13 JP JP2013124950A patent/JP5486719B2/ja active Active
- 2013-06-13 JP JP2013124949A patent/JP5486718B2/ja active Active
- 2013-06-13 JP JP2013124948A patent/JP5486717B2/ja active Active
- 2013-06-13 JP JP2013124951A patent/JP5486720B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ593225A (en) | Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis | |
| Orvis et al. | BRG1/SMARCA4 inactivation promotes non–small cell lung cancer aggressiveness by altering chromatin organization | |
| Lohavanichbutr et al. | Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices | |
| Han et al. | Long intergenic non‐coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder | |
| WO2004111273A3 (en) | Gene expression markers for response to egfr inhibitor drugs | |
| Barefoot et al. | Detection of cell types contributing to cancer from circulating, cell-free methylated DNA | |
| WO2008115419A3 (en) | Gene expression markers for prediction of patient response to chemotherapy | |
| WO2004071572A3 (en) | Gene expression markers for response to egfr inhibitor drugs | |
| NZ599194A (en) | Methods to predict clinical outcome of cancer | |
| NZ719474A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| WO2010118166A3 (en) | Methods of predicting cancer risk using gene expression in premalignant tissue | |
| NZ578283A (en) | Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring | |
| Gómez et al. | A novel method for rapid molecular subgrouping of medulloblastoma | |
| Qu et al. | Long non-coding RNA ROR is a novel prognosis factor associated with non-small-cell lung cancer progression | |
| WO2010088688A3 (en) | Diagnosis of in situ and invasive breast cancer | |
| WO2008103971A3 (en) | Prostate cancer survival and recurrence | |
| Fisel et al. | MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma | |
| EP3969608A1 (en) | Non-coding rna for subtyping of bladder cancer | |
| WO2005001138A3 (en) | Breast cancer survival and recurrence | |
| Jandova et al. | Sporadic early-onset colon cancer expresses unique molecular features | |
| Jaszek et al. | Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer—From Early Detection to Prognosis | |
| Ogidi et al. | Environmental DNA and RNA Metabarcoding: Advancing Insights in Cancer Research | |
| Parasramka et al. | Validation of gene expression signatures to identify low-risk clear-cell renal cell carcinoma patients at higher risk for disease-related death | |
| Chu et al. | Detection of ALK gene rearrangement in cell‐free RNA from lung cancer malignant pleural effusion | |
| Diao et al. | Development of a novel prognostic signature derived from enhancer RNA‐regulated genes in head neck squamous cell carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 JAN 2014 BY CPA GLOBAL Effective date: 20130425 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 JAN 2017 BY CPA GLOBAL Effective date: 20131129 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2018 BY COMPUTER PACKAGES INC Effective date: 20161220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2019 BY COMPUTER PACKAGES INC Effective date: 20171219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2020 BY COMPUTER PACKAGES INC Effective date: 20181218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2021 BY COMPUTER PACKAGES INC Effective date: 20191218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2022 BY COMPUTER PACKAGES INC Effective date: 20201218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2023 BY COMPUTER PACKAGES INC Effective date: 20211217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2024 BY COMPUTER PACKAGES INC Effective date: 20221217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2025 BY COMPUTER PACKAGES INC Effective date: 20231217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JAN 2026 BY COMPUTER PACKAGES INC Effective date: 20241217 |